EIF2AK3 and glaucoma: To the best of our knowledge, apart from GSK2606414, no other specific inhibitors of the PERK-dependent signaling pathway have extensively been evaluated in preclinical glaucoma models, which brings novelty to our present research on the effect of LDN-0060609 on ER stressed HTM cells.